Altogether, these data identify TGF-β as a relevant target to block the angiogenic switch in cancer patients and the inhibition of TGF-β signaling has been reported to preserve the function of highly activated, in vitro expanded NK cells in AML and CRC models [40] (Figure 1A). This evidence concerns the gene TGFB1 and colorectal carcinoma.